Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Trial of Therapy & Knowing When to Stop

A time-limited test with predefined goals

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (guidance)

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about trial of therapy & knowing when to stop in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

When TRT is genuinely indicated but uncertain to help, a structured trial of therapy is reasonable: define the target symptoms up front, treat for a defined period (commonly 3-6 months) with proper monitoring, and honestly assess whether those specific symptoms improved beyond placebo expectation. If they did not, the right decision is to stop and reconsider the diagnosis, not to escalate the dose. Because TRT suppresses the axis, even a 'trial' carries fertility and recovery implications, so this should be a deliberate, monitored process, not an open-ended subscription that simply continues by default. The default-to-continue business model works against this discipline.

If a 3-6 month trial doesn't clearly help, stopping is the right call.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Structuring and ending a therapeutic trial

What people get wrong

  • Often saidOnce you start TRT you have to stay on it no matter what

    ActuallyIf a properly monitored trial does not clearly help the target symptoms, stopping (with a recovery plan) is appropriate. Escalating the dose to chase a non-response is the wrong move.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Define
Target symptoms before starting
Duration
Commonly 3-6 months
If no clear benefit
Stop, don't escalate

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Trial of Therapy & Knowing When to Stop. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.